Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.43 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.43 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13725027 | 0.84 | AGXT (0.66) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL8189516 | 0.84 | AGXT (0.61) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL28773418 | 0.83 | AGXT (0.57) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL5673049 | 0.83 | AGXT (0.60) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL7954719 | 0.81 | SLC13A5 (0.49) | AGXTLMNAMEN1NPC1ALDH1A1 | |
| SCHEMBL22242840 | 0.80 | AGXT (0.57) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL13680781 | 0.80 | AGXT (0.57) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL108136 | 0.80 | AGXT (0.69) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL22964326 | 0.80 | AGXT (0.65) | AGXTLMNAKMOSIGMAR1ADRA2A | |
| SCHEMBL671148 | 0.80 | AGXT (0.65) | AGXTLMNAKMOSIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111386118-A | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | AGXT 584/4885LMNA 4323/4885KMO 4624/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | AGXT 803/4885LMNA 4306/4885KMO 4464/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | AGXT 803/4885LMNA 4306/4885KMO 4464/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | AGXT 1252/4885LMNA 4828/4885KMO 3248/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | AGXT 584/4885LMNA 4323/4885KMO 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.